Total Payments
$6,015
2021 Payments
$23.93
Companies
11
Transactions
52
Medicare Patients
2,612
Medicare Billing
$103,757
Payment Breakdown by Category
Other$5,237 (87.1%)
Food & Beverage$754.04 (12.5%)
Education$23.93 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $5,237 | 2 | 87.1% |
| Food and Beverage | $754.04 | 44 | 12.5% |
| Education | $23.93 | 1 | 0.4% |
| Unspecified | $0 | 5 | 0.0% |
Payments by Type
General
$6,015
47 transactions
Ownership
$0
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Innovative Medical Technologies, LLC | $5,237 | 7 | $0 (2021) |
| Astellas Pharma US Inc | $361.45 | 16 | $0 (2019) |
| AbbVie, Inc. | $146.63 | 11 | $0 (2017) |
| PFIZER INC. | $97.89 | 6 | $0 (2017) |
| Janssen Biotech, Inc. | $37.02 | 3 | $0 (2017) |
| Aytu Bioscience, Inc | $36.15 | 2 | $0 (2017) |
| Mission Pharmacal Company | $25.47 | 2 | $0 (2017) |
| Myovant Sciences Inc. | $23.93 | 1 | $0 (2021) |
| MEDIVATION INC. | $23.17 | 2 | $0 (2017) |
| Endo Pharmaceuticals Inc. | $14.08 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $23.93 | 2 | Myovant Sciences Inc. ($23.93) |
| 2020 | $0 | 1 | Innovative Medical Technologies, LLC |
| 2019 | $13.00 | 2 | Astellas Pharma US Inc ($13.00) |
| 2018 | $0 | 1 | Innovative Medical Technologies, LLC |
| 2017 | $5,978 | 46 | Innovative Medical Technologies, LLC ($5,237) |
All Payment Transactions
52 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/05/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 2021 | Innovative Medical Technologies, LLC | — | — | — | $0.00 | Ownership |
| 2020 | Innovative Medical Technologies, LLC | — | — | — | $0.00 | Ownership |
| 04/05/2019 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: UROLOGY | ||||||
| 2019 | Innovative Medical Technologies, LLC | — | — | — | $0.00 | Ownership |
| 2018 | Innovative Medical Technologies, LLC | — | — | — | $0.00 | Ownership |
| 11/15/2017 | PFIZER INC. | LYRICA (Drug) | Food and Beverage | In-kind items and services | $11.36 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 10/26/2017 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $118.56 | General |
| 08/29/2017 | Aytu Bioscience, Inc | Natesto (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Urology | ||||||
| 08/25/2017 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: ONCOLOGY | ||||||
| 08/11/2017 | Akrimax Pharmaceuticals, LLC | Stendra (Drug) | Food and Beverage | Cash or cash equivalent | $12.18 | General |
| Category: Erectile Dysfunction | ||||||
| 08/09/2017 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: ORTHOPEDICUROLOGY | ||||||
| 08/02/2017 | AbbVie, Inc. | Androgel (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Endocrinology | ||||||
| 07/21/2017 | PFIZER INC. | LYRICA (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 07/21/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi, Vesicare | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Urology | ||||||
| 07/19/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $104.77 | General |
| Category: Urology | ||||||
| 07/14/2017 | AbbVie, Inc. | Androgel (Drug), Lupron, Lupron | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: Endocrinology | ||||||
| 07/12/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Vesicare | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: Urology | ||||||
| 06/30/2017 | Janssen Biotech, Inc. | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $10.29 | General |
| Category: Oncology | ||||||
| 06/23/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $9.09 | General |
| Category: Urology | ||||||
| 06/23/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $6.15 | General |
| Category: Urology | ||||||
| 06/16/2017 | PFIZER INC. | LYRICA (Drug), XTANDI | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 05/31/2017 | Mission Pharmacal Company | Aquoral (Device) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Artificial Saliva (oral use) | ||||||
| 05/31/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: Urology | ||||||
| 05/26/2017 | Janssen Biotech, Inc. | ZYTIGA (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 112 | 114 | $8,550 | $2,479 |
| 2022 | 8 | 508 | 597 | $64,700 | $20,310 |
| 2021 | 13 | 1,023 | 1,357 | $140,004 | $46,743 |
| 2020 | 13 | 969 | 1,294 | $115,909 | $34,224 |
Total Patients
2,612
Total Services
3,362
Medicare Billing
$103,757
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 28 | $6,216 | $2,041 | 32.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 30 | 31 | $1,674 | $232.58 | 13.9% |
| 81002 | Urinalysis, manual test | Office | 2023 | 33 | 34 | $408.00 | $115.94 | 28.4% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2023 | 21 | 21 | $252.00 | $90.09 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 97 | $21,534 | $8,243 | 38.3% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 19 | 23 | $14,283 | $3,794 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 40 | 42 | $6,258 | $2,441 | 39.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 39 | 79 | $7,900 | $2,409 | 30.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 23 | 23 | $5,773 | $1,817 | 31.5% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2022 | 104 | 118 | $6,372 | $800.09 | 12.6% |
| 81002 | Urinalysis, manual test | Office | 2022 | 121 | 143 | $1,716 | $493.37 | 28.8% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2022 | 72 | 72 | $864.00 | $312.67 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 174 | 225 | $49,950 | $19,771 | 39.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 78 | 94 | $14,006 | $5,661 | 40.4% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 30 | 34 | $21,114 | $5,610 | 26.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 51 | 155 | $15,500 | $4,655 | 30.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 32 | 33 | $8,283 | $2,635 | 31.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2021 | 205 | 255 | $13,770 | $1,818 | 13.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $3,806 | $1,449 | 38.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 19 | 23 | $2,576 | $1,329 | 51.6% |
| 81002 | Urinalysis, manual test | Office | 2021 | 223 | 325 | $3,900 | $1,131 | 29.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 19 | $3,420 | $1,080 | 31.6% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2021 | 153 | 153 | $1,836 | $670.14 | 36.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 11 | $836.00 | $553.14 | 66.2% |
| 74420 | Imaging of urinary tract | Facility | 2021 | 17 | 19 | $1,007 | $379.05 | 37.6% |
About Frank Greco
Frank Greco is a Urology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295701860.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Frank Greco has received a total of $6,015 in payments from pharmaceutical and medical device companies, with $23.93 received in 2021. These payments were reported across 52 transactions from 11 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($5,237).
As a Medicare-enrolled provider, Greco has provided services to 2,612 Medicare beneficiaries, totaling 3,362 services with total Medicare billing of $103,757. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Pittsburgh, PA
- Active Since 02/24/2006
- Last Updated 03/25/2021
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1295701860
Products in Payments
- Myrbetriq (Drug) $198.31
- Androgel (Drug) $132.66
- LYRICA (Drug) $53.09
- XTANDI (Drug) $37.19
- ZYTIGA (Drug) $37.02
- Natesto (Drug) $36.15
- Xtandi (Drug) $31.58
- Aquoral (Device) $25.47
- ORGOVYX (Drug) $23.93
- VIAGRA (Drug) $21.16
- XIAFLEX (Biological) $14.08
- Lupron (Drug) $13.97
- MYRBETRIQ (Drug) $13.00
- Stendra (Drug) $12.18
- TOVIAZ (Drug) $9.62
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Pittsburgh
Mr. Quoc-Dien Trinh, M.d, M.D
Urology — Payments: $92,931
Urology $92,931
Kiran Sury, Md, MD
Urology — Payments: $56,475
Urology $56,475
Dr. Paul Rusilko, D.o, D.O
Urology — Payments: $40,004
Urology $40,004
Dr. Michelle Semins, Md, MD
Urology — Payments: $23,110
Urology $23,110
Mr. Jay Herman, Md, MD
Urology — Payments: $21,521
Urology $21,521
Dr. Arthur Thomas, M.d, M.D
Urology — Payments: $20,367
Urology $20,367